Services
Research coverage of emerging companies' stock is the starting point where the "eventuality" of an investment decision begins. It's extremely time consuming for the "buy-side" to have to do primary research on large numbers of stocks that may well end up being 'passed' on. For this same reason quant screens are often used to identify small companies that may be attractive on paper, but may "ignore" compelling qualitative factors that might "dictate" a future investment.
The central focus for Scimitar is optimizing the short, near and long term potential of an investment opportunity. Investors and shareholders need independent verification and review analyst reporting as one major source of verification that emerging healthcare companies are meeting milestones and reaching established goals.
Scimitar's comprehensive equity research is based on multiple approaches: detailed diligence, skepticism, translating expectation versus anticipation, evaluation and objectivity. We also remain open minded to contrary information as we initiate a thorough examination of the collected "intelligence" to develop an investment thesis. We strive for accuracy and completeness and restrict any influence or pressure for our investment thesis and valuation models. We are fully and solely committed to providing accurate and relevant insight.
Henry W. McCusker
Founder and Director of Research, Henry McCusker enters his seventh (7) year at Scimitar Equity, LLC.
Independent Equity Research
Scimitar Equity, LLC is an independent equity research firm focused on providing value-added intelligence and insightful investment conclusions on emerging companies demonstrating real progress toward their vision while meeting quarterly expectation.